Skip navigation EPAM

Insulet: Omnipod Management System

    • Case Study
    • Healthcare

    Diabetes is a life-threatening disease that affects nearly 30 million children and adults in the United States alone. When Insulet Corporation first partnered with EPAM Continuum, they were a three-person startup with a breakthrough idea for a new kind of insulin delivery system. Our team was tasked with turning Insulet’s vision into a reality by creating a subtle, pain-free and cost-effective alternative to traditional insulin pumps.

    Key Challenges

    The client envisioned an insulin patch that could adhere directly to the skin’s surface. This patch would automatically inject metered amounts of insulin according to the specific needs of the user, and be managed wirelessly via an integrated handheld device.

    The catch: the technology behind the patch didn’t exist yet, and the company had an aggressive timeline for development. EPAM Continuum assembled a team of ethnographers, designers, and engineers to help Insulet bring this revolutionary medical solution to the market.

    Solution Highlights

    With EPAM Continuum’s help, Insulet triggered a paradigm shift in diabetes management. The breakthrough Omnipod Insulin Delivery System—comprised of a disposable insulin patch and remote “Personal Diabetes Manager” (PDM)—was the world’s first FDA-approved, wireless, tube-free insulin pump. Now covered by a broad range of health insurance plans, the Omnipod provides an affordable diabetes management option that eliminates the discomfort and inconvenience of earlier therapies.

    Insulet’s Omnipod device is sold in multiple countries, most recently acquiring distribution rights in Canada. The company is also leveraging the Omnipod system for other subcutaneous drug therapies.

    The Results

    The commercial success of Omnipod launched Insulet Corporation from a three-person startup to a publicly traded company with over 500 employees. Their IPO raised $116 million in 2007, and since then, the company has grown steadily year over year. Insulet Corp.’s projected revenue for 2015 exceeds $280 million.

    The Omnipod system has also received broad support from health insurance providers because the up-front cost of the wireless controller and starter kit of disposable pumps is much lower than that of durable insulin pumps. Also appealing is the prescription payment model for the disposable pumps, which disperses coverage costs over time.

    Most importantly, Omnipod has given thousands of people a newfound sense of freedom and greater control managing their diabetes.

    You can find the original case study from EPAM Continuum here.

    Hello. How Can We Help You?

    Get in touch with us. We'd love to hear from you.

    Contact Us Contact Us

    Our Offices

    Canada Canada
    Colombia Colombia
    Mexico Mexico
    United States United States
    Armenia Armenia
    Austria Austria
    Belarus Belarus
    Bulgaria Bulgaria
    Czech Republic Czech Republic
    France France
    Georgia Georgia
    Germany Germany
    Hungary Hungary
    Ireland Ireland
    Italy Italy
    Kazakhstan Kazakhstan
    Lithuania Lithuania
    Malta Malta
    Netherlands Netherlands
    Poland Poland
    Romania Romania
    Spain Spain
    Sweden Sweden
    Switzerland Switzerland
    Ukraine Ukraine
    United Kingdom United Kingdom
    Uzbekistan Uzbekistan
    Australia Australia
    China China
    Hong Kong SAR Hong Kong SAR
    India India
    Japan Japan
    Singapore Singapore
    United Arab Emirates United Arab Emirates
    Vietnam Vietnam